Overview

Safety and Efficacy of Venetoclax, Cytarabine and Metformin (VenCM) for Relapsed-Refractory and Induction-Ineligible Acute Myeloid Leukemia

Status:
RECRUITING

Trial end date:
2028-07-01

Target enrollment:

Participant gender:

Summary

Phase 2 clinical trial to evaluate the combination of venetoclax, cytarabine and metformin in relapsed-refractory and induction ineligible acute myeloid leukemia.

Phase:

PHASE2

Details

Lead Sponsor:

Hospital Municipal São José

Collaborators:

Hospital Amaral Carvalho. Jau, SP, Brazil
Hospital de Clínicas da UFPR. Curitiba, PR, Brazil
Hospital Ophir Loyola. Belem, PA, Brazil
Hospital Universitario Polydoro Ernani de São Thiago. Florianopolis, SC, Brazil

Treatments:

Cytarabine
Metformin
venetoclax